Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
Completed · Phase 2 · NCT04781816
Conditions: Cutaneous Lupus Erythematosus
At a glance
- Research payments reported, 2025
- $5,000
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 78
About the trial
- Sponsor
- Sanofi
- Tested
- SAR443122 (drug), Placebo (drug)
- Dates
- Started 2021-04-01; completion 2023-06-26
- Results posted
- Yes
Primary Objective: * Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE) Secondary Objectives: * Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity) * Assess the effect of SAR443122 on CLE induced itch and overall pain * Assess the effect of SAR443122 on the proportion of disease activity responders compared to placebo * Assess the effect of SAR443122 on the CLASI components score * Assess the effect of SAR443122 on the Investigator's global assessment for CLE (IGA-CLE) * Assess oral cavities for patients with oral lesions * Assess the disease specific quality of life (QoL) * Assess the safety and tolerabi…
From ClinicalTrials.gov, last updated 2025-08-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $5,000 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Interspond LLC $5,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.